Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD Oct. 12, 2007 By Trista Morrison Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today)Read More
RSS